Navigation Links
Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information
Date:11/26/2014

PHILADELPHIA, Nov. 26, 2014 /PRNewswire/ -- Cohen, Placitella & Roth, PC is investigating potential claims on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: NYMX) during the period from January 31, 2011 through November 2, 2014 ("Class Period").  The investigation concerns whether Nymox and certain of its officers and directors publically disseminated materially false and/or misleading information in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, promulgated thereunder.

Nymox researches and develops therapeutic and diagnostic drugs, with an emphasis on targeting an aging U.S. population.  Since 2002, the Company has been developing a novel proprietary drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia ("BPH").   

Nymox touted the safety, efficacy and general viability of NX-1207 for over two years.  As recently as June 11 2014, Nymox issued a press release announcing "new clinical data supporting the positive safety profile of NX-1207" and that trials to date, including a second phase 3 trial of NX-1207 for BPH, titled NX02-0018, showed that men "treated with NX-1207 reported statistically significant improvement in BPH symptoms 3 months after a single NX-1207 treatment with no reported serious drug-related side effects."  The press release also stated "the absence of any significant drug-related side effects" unlike current approved drugs for BPH which "can produce significant sexual side effects."  Less than a week later, the Company issued another press release on June 17, 2014, that reported "new data supporting the positive sexual functional preservation profile of NX-1207."  By July 2014, the Company announced a new BPH re-injection study, and touted "new positive efficacy data for U.S. Study NX02-0022, the Company's repeat injection study of NX-1207 for BPH" in a July 22, 2014 press release.  On September 10, 2014, the Company announced via press release that NX-1207 had shown "positive outcome results" from an ongoing prospective trial for the treatment of low grade localized prostate cancer.

However, in a surprise to the market, and contrary to the positive statements concerning the NX02-0017 and NX02-0018 trials, Nymox disclosed on November 2, 2014 that the Company's two Phase 3 U.S. studies of NX-1207 (including NX02-0018) had to be halted because the drug failed to meets its primary endpoints for efficacy. 

On November 3, 2014, Nymox disclosed for the first time, among other things, the difficulties the Company faced in enrolling men for the trials and the subjective nature of the measurement of the drug's success.  In response to that news, the price of Nymox common stock fell 82% to close at $.93 in heavy trading volume of 19.6 million shares.  The Company's U.S. BPH program is currently on hold, pending further evaluation of data.

If you have any information about this investigation or, if you wish to discuss your rights as a shareholder in Nymox, please contact Eduardo A. Texidor, Jr., no later than January 12, 2015, at etexidor@cprlaw.com or, toll free, at 1-888-375-7600.  For those investors inquiring via email, please be sure to include "Nymox" in the subject line, the number of shares purchased, and your mailing address and telephone number.    

Since 1973, Cohen, Placitella & Roth, P.C. has been recognized as one of the premier trial law firms in the country.  The firm has extensive experience in prosecuting securities litigation involving violations of the federal securities laws, state law derivative actions and mergers and acquisitions cases, representing institutional investors such as public pension plans and union pension funds as well as individual shareholders suffering substantial investment losses due to corporate misconduct.  LexisNexis Martindale-Hubbell® annually reports Cohen, Placitella & Roth's peer rating-the highest AV® - "a testament to professional excellence."  Since the inauguration of its "Best Law Firms" edition in 2010, U.S. News and World Report has annually listed Cohen, Placitella & Roth's as one of the top-tier class action law firms in the country.

Contact:
Eduardo A. Texidor, Jr.
Cohen, Placitella & Roth, PC
Toll free: 1-888-375-7600
etexidor@cprlaw.com
www.cprlaw.com


'/>"/>
SOURCE Cohen, Placitella & Roth, P.C.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cohen, Placitella & Roth, P.C. Reminds NECC Victims of January 15, 2014 Claim Filing Deadline to Participate in any Bankruptcy Court distributions
2. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
3. BioLink 2015 Will be Held on Jan 22, 2015, with a Focus on Biopharma Industrial Innovation & International Technology Transfer
4. Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagens Toca 511 & Toca FC, Compared to Published Benchmarks
5. STAAR Surgical To Present At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum
6. Consilium Strategic Communications and Covington & Burling LLP to Host 2014 Annual Healthcare Conference "The Future of Healthcare - Funding Options, Innovation and M&A for 2015 and Beyond"
7. Optical Imaging Market by Technique (Optical Coherence Tomography, Hyperspectral Imaging, Photoacoustic Tomography), Product (Imaging System, Imaging software) & by Application (Ophthalmology, Neurology, Oncology, Cardiology) - Global Forecasts to 2
8. Janssen R&D and HemoShear Identify Vascular Health Benefits of Drugs Used to Treat Rheumatoid Arthritis
9. Salix Pharmaceuticals Ltd. Investigated by Block & Leviton LLP After The Company Announces Resignation Of Its Chief Financial Officer And Reduced Financial Forecasts
10. Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition
11. Frost & Sullivan Honours Acino Pharma for Pioneering Best Practices in the Pharmaceutical Drug Delivery Space
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):